The Year 2002 Process of Care: Guidelines for the Use of Aspirin in Cardioprotective Therapy

Please Note: This CME activity has expired. You may continue to view the material for educational purposes, but this activity is no longer eligible for CME credit.

Course Objectives:
This educational monograph is directed towards primary care, cardiology and endocrinology physicians.

Upon the completion of this activity, participants should be able to:

1. Evaluate current antiplatelet pharmacologic treatments for cardioprotective effects, including long-term safety and efficacy data and adverse event profiles.
2. Select appropriate agents for cardioprotective therapy and discuss optimal dosing schedules with respect to single-agent and combination therapies.
3. Identify current treatment guidelines and discuss their recommendations concerning primary and secondary cardioprotection.
4. Assess the incidence of side effects with different doses of aspirin.
5. Discuss the advantages/disadvantages of combination antiplatelet therapy for cardioprotection.

Accreditation:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of UMDNJ—Center for Continuing and Outreach Education and Millennium Medical Communications, Inc. UMDNJ—Center for Continuing and Outreach Education is accredited by the ACCME to provide continuing medical education for physicians.

UMDNJ—Center for Continuing and Outreach Education designates this educational activity for a maximum of 1.75 Category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This activity was prepared in accordance with the ACCME Essentials.

Faculty Disclosure:
The UMDNJ—Center for Continuing and Outreach Education endorses the Accreditation Council for Continuing Medical Education Standards for Commercial Support. Every effort has been made to encourage faculty to disclose any commercial relationships or personal benefit with companies whose products are discussed in educational presentations. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

The faculty listed below have declared that they have no financial arrangements or affiliations with any corporate organization offering financial support or grant monies for this CME program or with any corporate organization whose product(s) will be discussed in their presentation(s):

• Kimberly J.C. Carey, MS,CNM
• John B. Kostis,MD
• Michaeline Daboul
• Gurpreet Singh,MD
• Kim Dixon,MD
• Steven Steinhubl,MD
• David C.Howard
• Eric J. Topol,MD

The faculty listed below have declared the following arrangements and/or affiliations:

Peter Berger, MD: Grant/Research Support—Bristol-Myers Squibb, Johnson & Johnson, Merck, Sanofi-Synthelabo; Consultant—Bristol-Myers Squibb, Sanofi-Synthelabo

Deepak L. Bhatt, MD: Grant/Research Support—Aventis, Bristol-Myers Squibb, Merck, Millennium Pharmaceuticals, Sanofi-Synthelabo

William J. Elliott,MD, PhD: Dr. Elliott has served as a consultant for, was a grant recipient of, and/or has served on the Speakers Bureau of Abbott, AstraZeneca, Aventis, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Curative Technologies, Eli Lilly, Forest, GlaxoSmithKline, ICI Pharma, Key, Knoll, Kos,Merck, Neurex, Novartis, Parke-Davis/Pfizer, Pharmacia, Procter & Gamble, Roche, Sankyo, Schwarz Pharma, Solvay, Unimed, and Wyeth

Shamir Mehta, MD: Grant/Research Support—Bristol-Myers Squibb, Sanofi-Synthelabo; Consultant—Bristol-Myers Squibb, Sanofi-Synthelabo; Speakers Bureau—Bristol-Myers Squibb, Sanofi-Synthelabo

Signed Disclosure forms are on file at the UMDNJ—Center for Continuing and Outreach Education.

Directions:
The learner should read the learning objectives and study the publication. After analyzing the material, the learner should complete the self-assessment test consisting of a series of multiple-choice questions, followed by the activity evaluation.

Upon completing this activity as designed, described above, and achieving a passing score of 70% or more on the self-assessment test, participants will receive a letter of credit awarding AMA/PRA Category 1 credit.

Estimated time to complete this activity as designed is 1.75 hours.

This activity was reviewed for relevance, accuracy of content, balance of presentation, and time required for participation by John B. Kostis, MD, Kim Dixon, MD, and Gurpreet Singh, MD.

Additional Information:
For this activity, please direct CME related questions to UMDNJ at (800) 227-4852 or email ccoe@umdnj.edu.

A web enabled computer is the only requirement necessary to complete this online activity. To view or print the course material, a PDF viewer such as Adobe's Acrobat Reader (free download) must be installed. If you encounter any difficulties and require technical support, please contact Millennium CME Institute at support@millennium-CME.com.

To review UMDNJ's privacy policy, please click here.

CME Testing Options